Angermann Christiane E, Sehner Susanne, Faller Hermann, Güder Gülmisal, Morbach Caroline, Frantz Stefan, Wegscheider Karl, Ertl Georg, Störk Stefan T
Comprehensive Heart Failure Centre, University and University Hospital Würzburg, Würzburg, Germany; Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany.
Medical Centre Hamburg-Eppendorf (UKE), Institute of Medical Biometry and Epidemiology, Hamburg, Germany.
JACC Heart Fail. 2023 Feb;11(2):191-206. doi: 10.1016/j.jchf.2022.10.016. Epub 2023 Jan 11.
The randomized INH (Interdisciplinary Network Heart Failure) trial (N = 715) reported that 6 months' remote patient management (RPM) (HeartNetCare-HF) did not reduce the primary outcome (time to all-cause death/rehospitalization) vs usual care (UC) in patients discharged after admission for acute heart failure, but suggested lower mortality and better quality of life in the RPM group.
The Extended (E)-INH trial investigated the effects of 18 months' HeartNetCare-HF on the same primary outcome in an expanded population (N = 1,022) and followed survivors up to 60 months (primary outcome events) or up to 120 months (mortality) after RPM termination.
Eligible patients aged ≥18 years, hospitalized for acute heart failure, and with predischarge ejection fraction ≤40% were randomized to RPM (RPM+UC; n = 509) or control (UC; n = 513). Follow-up visits were every 6 months during RPM, and then at 36, 60, and 120 months.
The primary outcome did not differ between groups at 18 months (60.7% [95% CI: 56.5%-65.0%] vs 61.2% [95% CI: 57.0%-65.4%]) or 60 months (78.1% [95% CI: 74.4%-81.6%] vs 82.8% [95% CI: 79.5%-86.0%]). At 60 and 120 months, all-cause mortality was lower in patients previously undergoing RPM (41.1% [95% CI: 37.0%-45.5%] vs 47.4% [95% CI: 43.2%-51.8%]; P = 0.040 and 64.0% [95% CI: 59.8%-68.2%] vs 69.6% [95% CI: 65.6%-73.5%]; P = 0.019). At all visits, health-related quality of life was better in patients exposed to HeartNetCare-HF vs UC.
Although 18 months' HeartNetCare-HF did not significantly reduce the primary outcome of death or rehospitalization at 60 months, lower 120-month mortality in patients previously undergoing HeartNetCare-HF suggested beneficial longer-term effects, although the possibility of a chance finding remains.
随机化的INH(跨学科网络心力衰竭)试验(N = 715)报告称,对于因急性心力衰竭入院后出院的患者,6个月的远程患者管理(RPM)(HeartNetCare-HF)与常规治疗(UC)相比,并未降低主要结局(全因死亡/再住院时间),但提示RPM组死亡率更低且生活质量更好。
扩展(E)-INH试验在扩大的人群(N = 1,022)中研究了18个月的HeartNetCare-HF对相同主要结局的影响,并在RPM终止后对幸存者随访至60个月(主要结局事件)或120个月(死亡率)。
年龄≥18岁、因急性心力衰竭住院且出院前射血分数≤40%的符合条件患者被随机分为RPM组(RPM + UC;n = 509)或对照组(UC;n = 513)。在RPM期间每6个月进行一次随访,然后在36、60和120个月时进行随访。
18个月时(60.7% [95% CI:56.5%-65.0%] 对61.2% [95% CI:57.0%-65.4%])或60个月时(78.1% [95% CI:74.4%-81.6%] 对82.8% [95% CI:79.5%-86.0%]),两组主要结局无差异。在60和120个月时,先前接受RPM治疗的患者全因死亡率较低(41.1% [95% CI:37.0%-45.5%] 对47.4% [95% CI:43.2%-51.8%];P = 0.040,以及64.0% [95% CI:59.8%-68.2%] 对69.6% [95% CI:65.6%-73.5%];P = 0.019)。在所有随访中,接受HeartNetCare-HF治疗的患者与接受UC治疗的患者相比,健康相关生活质量更好。
尽管18个月的HeartNetCare-HF在60个月时未显著降低死亡或再住院的主要结局,但先前接受HeartNetCare-HF治疗的患者120个月时死亡率较低,提示有有益的长期影响,尽管仍有可能是偶然发现。